Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population

References

• Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Models Mech. 2013;6(2):281–292. doi:10.1242/dmm.010561
   PubMed Web of Science ®Google Scholar
• Ladep NG, Khan SA, Crossey M, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World J Gastroenterol. 2014;20(6):1544–1553. doi:10.3748/wjg.v20.i6.154424587630
   PubMed Web of Science ®Google Scholar
• Khan S, Cox I, Thillainayagam AV, Bansi D, Thomas HC, Taylor-Robinson S. Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreatico-biliary cancer. Eur J Gastroenterol Hepatol. 2005;17(7):733–738. doi:10.1097/00042737-200507000-0000715947550
   PubMed Web of Science ®Google Scholar
• Xiao JF, Zhou B, Ressom HW. Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trends Analyt Chem. 2012;32:1–14. doi:10.1016/j.trac.2011.08.009
   PubMed Web of Science ®Google Scholar
• Wishart DS, Jewison T, Guo AC, et al. Hmdb 3.0—the human metabolome database in 2013. Nucleic Acids Res. 2013;41:801–807.
   PubMed Web of Science ®Google Scholar
• Smith CA, Want EJ, Qin C, et al. Metlin: A metabolite mass spectral database. Drug Monit. 2005;27:747–751. doi:10.1097/01.ftd.0000179845.53213.39
   PubMed Web of Science ®Google Scholar
• Dadhwal U, Kumar V. Benign bile duct strictures. Med J Armed Forces India. 2012;68(3):299. doi:10.1016/j.mjafi.2012.04.01424532893
   PubMedGoogle Scholar
• Singh A, Gelrud A, Agarwal B. Biliary strictures: diagnostic considerations and approach. Gastroenterol Rep. 2015;3(1):22–31. doi:10.1093/gastro/gou072
   Google Scholar
• Bell LN, Wulff J, Comerford M, Vuppalanchi R, Chalasani N. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int. 2015;35(1):263–274. doi:10.1111/liv.1268025181933
   PubMed Web of Science ®Google Scholar
• AbdAlla H, Taylor-Robinson SD, Sharif AW, et al. Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma. Hpb. 2011;13(6):385–390. doi:10.1111/j.1477-2574.2011.00296.x21609370
   PubMed Web of Science ®Google Scholar
• Sharif AW, Williams HR, Lampejo T, et al. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. Hpb. 2010;12(6):396–402. doi:10.1111/j.1477-2574.2010.00185.x20662790
   PubMed Web of Science ®Google Scholar
• Albiin N, Smith I, Arnelo U, et al. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta radiol. 2008;49(8):855–862. doi:10.1080/0284185080222009218608012
   PubMed Web of Science ®Google Scholar
• Schmuck RB, Carvalho-Fischer CV, Neumann C, Pratschke J, Bahra M. Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Med. 2016;5(1):88–99. doi:10.1002/cam4.2016.5.issue-126645826
   PubMed Web of Science ®Google Scholar
• Ballehaninna UK, Chamberlain RS. The clinical utility of serum ca 19-9 in the diag- nosis, prognosis and management of pancreatic adenocarcinoma: an evidence-based appraisal. J Gastrointest Oncol. 2011;3(2):105–119.
   Google Scholar
• Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by 1h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2011;11(2):1274–1283. doi:10.1021/pr200960u22066465
   PubMed Web of Science ®Google Scholar
• Di Gangi IM, Mazza T, Fontana A, et al. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7(5):5815. doi:10.18632/oncotarget.680826735340
   PubMedGoogle Scholar
• Ritchie SA, Akita H, Takemasa I, et al. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13(1):416. doi:10.1186/1471-2407-13-41624024929
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Bertuccio P, Rosso T, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26(4):779–786. doi:10.1093/annonc/mdv38325623049
   PubMed Web of Science ®Google Scholar
• Reshetnyak VI. Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol. 2012;4(2):18–34. doi:10.4254/wjh.v4.i2.1822400083
   PubMedGoogle Scholar
• Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172–187. doi:10.5009/gnl.2012.6.2.17222570746
   PubMed Web of Science ®Google Scholar
• Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 6th ed. Abingdon: Taylor & Francis Group; 2014:252.
   Google Scholar
• Aird KM, Zhang R. Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett. 2015;356(2):204–210. doi:10.1016/j.canlet.2014.01.01724486217
   PubMed Web of Science ®Google Scholar
• Seidel A, Seidel P, Manuwald O, Herbarth O. Modified nucleosides as biomarkers for early cancer diagnose in exposed populations. Environ Toxicol. 2015;30(8):956–967. doi:10.1002/tox.v30.824615900
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Koyama H, Kurajoh M, Shoji T, Tsutsumi Z, Moriwaki Y. Biochemistry of uridine in plasma. Clin Chim Acta. 2011;412(19):1712–1724. doi:10.1016/j.cca.2011.06.00621689643
   PubMed Web of Science ®Google Scholar
• Ma WW, Saif WM, El-Rayes BF, et al. Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity. Journal of Clinical Oncology. 2016. doi:10.1200/jco.2016.34.4_suppl.655
   Web of Science ®Google Scholar
• Ka T, Inokuchi T, Tamada D, et al. Relationship between plasma uridine and urinary urea excretion. Metabolism. 2010;59(3):441–445. doi:10.1016/j.metabol.2009.07.03219846174
   PubMed Web of Science ®Google Scholar
• Gasser T, Moyer JD, Handschumacher RE. Novel single-pass exchange of circulating uridine in rat liver. Science. 1981;213(4509):777–778. doi:10.1126/science.72562797256279
   PubMed Web of Science ®Google Scholar
• Le TT, Ziemba A, Urasaki Y, Hayes E, Brotman S, Pizzorno G. Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation. J Lipid Res. 2013;54(4):1044–1057. doi:10.1194/jlr.M03424923355744
   PubMed Web of Science ®Google Scholar
• Magyar I, Loi H, Feher T. Plasma bile acid levels and liver disease. Acta Med Acad Sci Hung. 1980;38(2):109–111.
   Google Scholar
• Trottier J, Bia3ek A, Caron P, Straka RJ, Milkiewicz P, Barbier O. Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting. PLoS One. 2011;6(7):e22094. doi:10.1371/journal.pone.002209421760958
   PubMed Web of Science ®Google Scholar
• Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom. 2010;24(5):613–620. doi:10.1002/rcm.v24:520143319
   PubMed Web of Science ®Google Scholar
• Wu Z, Lu Y, Wang B, Liu C, Wang Z-R. Effects of bile acids on proliferation and ultrastructural alteration of pancreatic cancer cell lines. World J Gastroenterol. 2003;9(12):2759–2763. doi:10.3748/wjg.v9.i12.275914669328
   PubMed Web of Science ®Google Scholar
• Feng H-Y, Chen Y-C. Role of bile acids in carcinogenesis of pancreatic cancer: an old topic with new perspective. World J Gastroenterol. 2016;22(33):7463. doi:10.3748/wjg.v22.i37.831427672269
   PubMed Web of Science ®Google Scholar